New drug combo for intermediate/high risk AML
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new combination of drugs (VA plus HAAG) for adults newly diagnosed with intermediate or high-risk AML. It aims to see if this combination is safe and effective for people who haven't had prior treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have been newly diagnosed with acute myeloid leukemia (AML) that is intermediate or high risk (not a low-risk type).
- You have not had any chemotherapy or targeted therapy before.
- Your liver and kidney function tests are within certain safe limits (doctors will check).
- You do not have an uncontrolled infection, HIV, active hepatitis B or C, or another cancer needing treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (venetoclax, homoharringtonine, and azacitidine) plus a growth factor to treat newly diagnosed AML in people who aren't strong enough for standard chemo. The goal is to see if this combo can help control the leukemia with fewer side effects.
This trial tests a combination of three drugs (venetoclax, azacitidine, and homoharringtonine) followed by a donor stem cell transplant for people with intermediate- or high-risk acute myeloid leukemia (AML). The goal is to see if this approach can improve outcomes for patients who have not been treated before.
This trial tests the combination of venetoclax (a targeted pill) and azacitidine (a chemotherapy-like drug) as consolidation therapy after initial treatment in adults with high-risk acute myeloid leukemia (AML) who have achieved remission and are planning a stem cell transplant. The goal is to see if this combination helps prevent relapse before transplant.
This trial tests a combination of two drugs, venetoclax and a hypomethylating agent (HMA), as the first treatment for adults with a type of leukemia called AML. The goal is to see if this combination works well and is safe for patients who have not had prior chemotherapy.
This trial tests a new drug combination (venetoclax plus CACAG chemotherapy) for people whose acute myeloid leukemia has come back or not responded to earlier treatments. The goal is to see if this combination can help control the leukemia.
This trial tests a new combination therapy called VAG for people with acute myeloid leukemia (AML) who haven't been treated before. The goal is to see if it works better than standard treatments.
Hear when a new Intermediate Risk Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.